Y Pan1, M S Kao. 1. Department of Neurology and Psychiatry, Saint Louis University, St. Louis, MO, U.S.A.
Abstract
UNLABELLED: Aromatase inhibitors have not been adequately assessed in treatment of ovarian cancer. The aromatase inhibitor letrozole (2.5 mg daily) was administered in 2 cases of advanced endometrioid ovarian cancer with positive estrogen receptor. CASE 1: A 52-year-old woman with a grade 2-3, stage iiic endometrioid ovarian cancer was optimally debulked and received 6 cycles of intravenous paclitaxel and intraperitoneal cisplatin-paclitaxel. Post chemotherapy, one of several biopsies showed residual disease during the second-look laparoscopy. This patient was treated with letrozole and remained disease-free during 30 months of follow-up. CASE 2: A 47-year-old woman with a grade 3, stage iiic endometrioid ovarian cancer was optimally debulked and treated with intravenous carboplatin-paclitaxel. After a 15-month remission, her first recurrent disease was treated with carboplatin-docetaxel. The second remission lasted only 11 months, after which the patient was treated with splenectomy and subsequent liposomal doxorubicin. Letrozole was administered after the chemotherapy. The patient had a 30-month remission before the next recurrence of her disease. CONCLUSIONS: Endometrioid ovarian carcinoma may benefit from aromatase inhibitors, especially when the tumour burden is low after primary chemotherapy or when the inhibitor is used as maintenance therapy between chemotherapies.
UNLABELLED: Aromatase inhibitors have not been adequately assessed in treatment of ovarian cancer. The aromatase inhibitor letrozole (2.5 mg daily) was administered in 2 cases of advanced endometrioid ovarian cancer with positive estrogen receptor. CASE 1: A 52-year-old woman with a grade 2-3, stage iiic endometrioid ovarian cancer was optimally debulked and received 6 cycles of intravenous paclitaxel and intraperitoneal cisplatin-paclitaxel. Post chemotherapy, one of several biopsies showed residual disease during the second-look laparoscopy. This patient was treated with letrozole and remained disease-free during 30 months of follow-up. CASE 2: A 47-year-old woman with a grade 3, stage iiic endometrioid ovarian cancer was optimally debulked and treated with intravenous carboplatin-paclitaxel. After a 15-month remission, her first recurrent disease was treated with carboplatin-docetaxel. The second remission lasted only 11 months, after which the patient was treated with splenectomy and subsequent liposomal doxorubicin. Letrozole was administered after the chemotherapy. The patient had a 30-month remission before the next recurrence of her disease. CONCLUSIONS:Endometrioid ovarian carcinoma may benefit from aromatase inhibitors, especially when the tumour burden is low after primary chemotherapy or when the inhibitor is used as maintenance therapy between chemotherapies.
Authors: John F Smyth; Charlie Gourley; Graeme Walker; Melanie J MacKean; Alan Stevenson; Alistair R W Williams; Awatif Al Nafussi; Tzyvia Rye; Ron Rye; Moira Stewart; Janet McCurdy; Max Mano; Nick Reed; Tracey McMahon; Paul Vasey; Hani Gabra; Simon P Langdon Journal: Clin Cancer Res Date: 2007-06-15 Impact factor: 12.531
Authors: Pedro T Ramirez; Kathleen M Schmeler; Michael R Milam; Brian M Slomovitz; Judith A Smith; John J Kavanagh; Michael Deavers; Charles Levenback; Robert L Coleman; David M Gershenson Journal: Gynecol Oncol Date: 2008-05-05 Impact factor: 5.482
Authors: Marcela G del Carmen; Arlan F Fuller; Ursula Matulonis; Nora K Horick; Annekathryn Goodman; Linda R Duska; Richard Penson; Susana Campos; Maria Roche; Michael V Seiden Journal: Gynecol Oncol Date: 2003-12 Impact factor: 5.482
Authors: Angela Bowman; Hani Gabra; Simon P Langdon; Alastair Lessells; Moira Stewart; Ann Young; John F Smyth Journal: Clin Cancer Res Date: 2002-07 Impact factor: 12.531
Authors: G Bertelli; E Hall; E Ireland; C F Snowdon; J Jassem; K Drosik; H Karnicka-Mlodkowska; R C Coombes; J M Bliss Journal: Ann Oncol Date: 2009-08-28 Impact factor: 32.976
Authors: Peter Rambau; Linda E Kelemen; Helen Steed; May Lynn Quan; Prafull Ghatage; Martin Köbel Journal: Int J Mol Sci Date: 2017-02-27 Impact factor: 5.923